Pre-Market Most Active for May 28, 2025 : SPRO, LVWR, TSLL, NVTS, NVDA, SQQQ, GME, BBAI, TSLA, QBTS, JOBY, IONQ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 57.38 points, with a total volume of 256,613,012 shares traded, highlighting active stocks like Spero Therapeutics and Tesla showing significant price movements.
Stock Highlights: Notable pre-market stock performances include Spero Therapeutics at $2.35 (up 47% from target), Tesla at $366.00 (122% of target), and GameStop at $35.95 (266.3% of target), while D-Wave Quantum and IonQ show mixed results with recommendations in the "buy range."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 219.510
Low
200.00
Averages
264.97
High
352.00
Current: 219.510
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is an artificial intelligence (AI) infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. Its segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing and networking platforms and AI solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment includes GeForce GPUs for gaming and personal computers (PCs), and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. Its technology stack includes the foundational NVIDIA CUDA development platform that runs on all NVIDIA GPUs, as well as hundreds of domain-specific software libraries, frameworks, algorithms, software development kits (SDKs), and application programming interfaces (APIs). Its platforms address four markets, which include Data Center, Gaming, Professional Visualization, and Automotive.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nvidia Announces $80 Billion Stock Buyback Amid AI Growth
- Earnings Beat: Nvidia's first-quarter results exceeded Wall Street expectations, showcasing robust growth in its data center business amid accelerating AI infrastructure investments, which reflects management's confidence in future revenue and profit expansion.
- Massive Buyback Authorization: The board approved an additional $80 billion stock repurchase program, indicating management's belief that the current stock price is undervalued and aiming to enhance shareholder confidence through capital return.
- Historical Buyback Trends: Over the past year, Nvidia has authorized more than $25 billion in stock buybacks, demonstrating a consistent capital return strategy, particularly returning over $41.1 billion to shareholders through buybacks and dividends in fiscal 2026.
- Attractive Market Valuation: With a current P/E ratio of 25 times expected earnings, Nvidia appears relatively undervalued compared to historical premiums during AI expansion phases, making the buyback decision not just a capital return but a strong signal of future growth potential.
See More
SpaceX IPO Expected to Be Largest in History
- Massive Capital Raise: SpaceX aims to raise approximately $75 billion through its IPO, with a valuation between $1.75 trillion and $2 trillion, positioning it as potentially the largest IPO in history and attracting significant investor interest.
- Infrastructure Supplier Dependence: While SpaceX's IPO garners attention, history indicates that infrastructure suppliers like Nvidia often achieve higher long-term returns, highlighting the market's ongoing demand for essential technology support.
- Clear Funding Utilization: The IPO proceeds will be directed towards expanding the Starlink network, enhancing Starship reusability, and designing data centers that could be deployed in orbit, all of which require substantial GPU support, thereby reinforcing the partnership with Nvidia.
- Expected Market Volatility: SpaceX stock is anticipated to experience typical post-IPO volatility, particularly after lock-up periods expire when insiders may begin to take profits, while Nvidia could benefit from the influx of capital due to its dominant position in AI infrastructure.
See More
Analysis of SpaceX IPO Prospects and Investment Risks
- IPO Market Performance: A Reuters analysis reveals that among the 50 highest-valued IPOs in the past five years, investors would have been better off investing in an S&P 500 index fund about two-thirds of the time, highlighting the investment risks associated with IPOs.
- SpaceX Valuation Challenges: SpaceX is expected to debut with a valuation of $1.75 trillion, yet its nearly 100 price-to-sales ratio significantly exceeds AI giant Nvidia's 24, indicating that high valuations may expose investors to greater risk of losses.
- Investor Participation Opportunities: Founder Elon Musk is making some shares available to retail investors through platforms like Robinhood and SoFi; however, Reuters' analysis suggests that investors buying on the first day of trading often face greater losses.
- Market Volatility and Returns: While AI-related companies like Astera Labs and Arm Holdings have shown impressive gains of 700% and 400% respectively, the disappointing performances of companies like Didi Global and Rivian Automotive illustrate the high uncertainty in the market.
See More
Recursion Pharmaceuticals Faces Challenges Despite AI Innovations
- Poor Market Performance: Recursion Pharmaceuticals' stock has significantly underperformed broader equities over the past two years, recently hitting a new 52-week low, reflecting market skepticism regarding its AI-driven drug development strategy, which may lead to investor concerns about future performance.
- Partnerships Enhance Confidence: Collaborations with industry giants like Nvidia, Roche, Sanofi, and Bayer indicate potential in its technology; however, the lack of tangible results undermines market confidence in its financing capabilities and clinical progress.
- High R&D Costs: The time and costs associated with new drug development have risen sharply over the decades, and while Recursion aims to reduce these through its AI system, it currently lacks market-ready products and faces significant clinical and regulatory risks.
- Uncertain Clinical Trial Outlook: Although REC-4881 shows promise in treating Familial Adenomatous Polyposis, it remains in early-stage studies with no late-stage candidates, necessitating caution from investors regarding its future clinical advancements.
See More
Nvidia's Massive Dividend Increase Sparks Interest
- Significant Dividend Increase: Nvidia recently announced a dividend increase from $0.01 to $0.25 per share, representing a 2,400% rise, which marks a substantial shift in its dividend policy and may attract more income-focused investors.
- Strong Earnings Coverage: With a diluted earnings per share of $2.39 reported in its latest quarterly results, Nvidia can easily cover a year's worth of dividend payments, showcasing its robust financial health and potential for continued growth.
- Yield Comparison: Although Nvidia's dividend yield stands at approximately 0.47%, which is still below the S&P 500 average of 1.1% and Microsoft's 0.87%, it surpasses Apple's 0.35%, indicating its competitive position among tech stocks.
- Preferred by Growth Investors: Despite the dividend increase, Nvidia remains primarily a growth stock, and investors should focus on the potential for capital appreciation rather than the relatively modest dividend income.
See More
Recursion Pharmaceuticals Leverages AI to Enhance Drug Development
- AI-Driven Drug Development: Recursion Pharmaceuticals is leveraging artificial intelligence to enhance drug development processes, aiming to shorten the time and costs associated with the drug discovery phase, although it has yet to demonstrate significant market results.
- Partnerships: The company has formed partnerships with industry giants such as Nvidia, Roche, Sanofi, and Bayer, which not only validate the potential value of its approach but may also facilitate access to non-dilutive financing.
- Clinical Trial Progress: Recursion's ongoing clinical trial for REC-4881 shows promise in significantly reducing polyp burden in patients with Familial Adenomatous Polyposis, although the drug still faces a lengthy approval process ahead.
- Poor Market Performance: Despite its innovative AI-driven strategy and strong partnerships, Recursion's stock has underperformed over the past two years, recently hitting a 52-week low, reflecting market caution regarding its future prospects.
See More
Nvidia Announces $80 Billion Stock Buyback Amid AI Growth
- Earnings Beat: Nvidia's first-quarter results exceeded Wall Street expectations, showcasing robust growth in its data center business amid accelerating AI infrastructure investments, which reflects management's confidence in future revenue and profit expansion.
- Massive Buyback Authorization: The board approved an additional $80 billion stock repurchase program, indicating management's belief that the current stock price is undervalued and aiming to enhance shareholder confidence through capital return.
- Historical Buyback Trends: Over the past year, Nvidia has authorized more than $25 billion in stock buybacks, demonstrating a consistent capital return strategy, particularly returning over $41.1 billion to shareholders through buybacks and dividends in fiscal 2026.
- Attractive Market Valuation: With a current P/E ratio of 25 times expected earnings, Nvidia appears relatively undervalued compared to historical premiums during AI expansion phases, making the buyback decision not just a capital return but a strong signal of future growth potential.
See More
SpaceX IPO Expected to Be Largest in History
- Massive Capital Raise: SpaceX aims to raise approximately $75 billion through its IPO, with a valuation between $1.75 trillion and $2 trillion, positioning it as potentially the largest IPO in history and attracting significant investor interest.
- Infrastructure Supplier Dependence: While SpaceX's IPO garners attention, history indicates that infrastructure suppliers like Nvidia often achieve higher long-term returns, highlighting the market's ongoing demand for essential technology support.
- Clear Funding Utilization: The IPO proceeds will be directed towards expanding the Starlink network, enhancing Starship reusability, and designing data centers that could be deployed in orbit, all of which require substantial GPU support, thereby reinforcing the partnership with Nvidia.
- Expected Market Volatility: SpaceX stock is anticipated to experience typical post-IPO volatility, particularly after lock-up periods expire when insiders may begin to take profits, while Nvidia could benefit from the influx of capital due to its dominant position in AI infrastructure.
See More
Analysis of SpaceX IPO Prospects and Investment Risks
- IPO Market Performance: A Reuters analysis reveals that among the 50 highest-valued IPOs in the past five years, investors would have been better off investing in an S&P 500 index fund about two-thirds of the time, highlighting the investment risks associated with IPOs.
- SpaceX Valuation Challenges: SpaceX is expected to debut with a valuation of $1.75 trillion, yet its nearly 100 price-to-sales ratio significantly exceeds AI giant Nvidia's 24, indicating that high valuations may expose investors to greater risk of losses.
- Investor Participation Opportunities: Founder Elon Musk is making some shares available to retail investors through platforms like Robinhood and SoFi; however, Reuters' analysis suggests that investors buying on the first day of trading often face greater losses.
- Market Volatility and Returns: While AI-related companies like Astera Labs and Arm Holdings have shown impressive gains of 700% and 400% respectively, the disappointing performances of companies like Didi Global and Rivian Automotive illustrate the high uncertainty in the market.
See More
Recursion Pharmaceuticals Faces Challenges Despite AI Innovations
- Poor Market Performance: Recursion Pharmaceuticals' stock has significantly underperformed broader equities over the past two years, recently hitting a new 52-week low, reflecting market skepticism regarding its AI-driven drug development strategy, which may lead to investor concerns about future performance.
- Partnerships Enhance Confidence: Collaborations with industry giants like Nvidia, Roche, Sanofi, and Bayer indicate potential in its technology; however, the lack of tangible results undermines market confidence in its financing capabilities and clinical progress.
- High R&D Costs: The time and costs associated with new drug development have risen sharply over the decades, and while Recursion aims to reduce these through its AI system, it currently lacks market-ready products and faces significant clinical and regulatory risks.
- Uncertain Clinical Trial Outlook: Although REC-4881 shows promise in treating Familial Adenomatous Polyposis, it remains in early-stage studies with no late-stage candidates, necessitating caution from investors regarding its future clinical advancements.
See More
Nvidia's Massive Dividend Increase Sparks Interest
- Significant Dividend Increase: Nvidia recently announced a dividend increase from $0.01 to $0.25 per share, representing a 2,400% rise, which marks a substantial shift in its dividend policy and may attract more income-focused investors.
- Strong Earnings Coverage: With a diluted earnings per share of $2.39 reported in its latest quarterly results, Nvidia can easily cover a year's worth of dividend payments, showcasing its robust financial health and potential for continued growth.
- Yield Comparison: Although Nvidia's dividend yield stands at approximately 0.47%, which is still below the S&P 500 average of 1.1% and Microsoft's 0.87%, it surpasses Apple's 0.35%, indicating its competitive position among tech stocks.
- Preferred by Growth Investors: Despite the dividend increase, Nvidia remains primarily a growth stock, and investors should focus on the potential for capital appreciation rather than the relatively modest dividend income.
See More
Recursion Pharmaceuticals Leverages AI to Enhance Drug Development
- AI-Driven Drug Development: Recursion Pharmaceuticals is leveraging artificial intelligence to enhance drug development processes, aiming to shorten the time and costs associated with the drug discovery phase, although it has yet to demonstrate significant market results.
- Partnerships: The company has formed partnerships with industry giants such as Nvidia, Roche, Sanofi, and Bayer, which not only validate the potential value of its approach but may also facilitate access to non-dilutive financing.
- Clinical Trial Progress: Recursion's ongoing clinical trial for REC-4881 shows promise in significantly reducing polyp burden in patients with Familial Adenomatous Polyposis, although the drug still faces a lengthy approval process ahead.
- Poor Market Performance: Despite its innovative AI-driven strategy and strong partnerships, Recursion's stock has underperformed over the past two years, recently hitting a 52-week low, reflecting market caution regarding its future prospects.
See More
